Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease

Movement Disorders

Volumn 31, Issue 3, 2016, Pages 325-334

  Barbagallo, Gaetano ^a,b,c   Sierra Peña, Maria ^d   Nemmi, Federico ^e   Traon, Anne Pavy Le ^f   Meissner, Wassilios G ^g,h,i   Rascol, Olivier ^a,b,f   Péran, Patrice ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e KAROLINSKA INSTITUTE   (Sweden)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

Multimodal MRI; Multiple system atrophy; Nigro striatal pathway; Parkinson's disease

Indexed keywords

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORPUS STRIATUM; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; MIDDLE AGED; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; AGED; DIAGNOSTIC IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AGED; CORPUS STRIATUM; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PUTAMEN;

EID: 84951958333     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26471     Document Type: Article

References (65)

1. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992;55:1009-1013.
2. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013;12:264-274.
3. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
4. Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord 2005;20(Suppl 12):S67-S76.
5. Wenning GK, Seppi K, Tison F, Jellinger K. A novel grading scale for striatonigral degeneration (multiple system atrophy). J Neural Transm 2002;109:307-320.
6. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
7. Brooks DJ, Seppi K; Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24:949-964.
8. Messina D, Cerasa A, Condino F, et al. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Parkinsonism Relat Disord 2011;17:172-176.
9. Shin HY, Kang SY, Yang JH, Kim HS, Lee MS, Sohn YH. Use of the putamen/caudate volume ratio for early differentiation between parkinsonian variant of multiple system atrophy and Parkinson disease. J Clin Neurol 2007;3:79-81.
10. Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999;56:225-228.
11. Lee JH, Han YH, Kang BM, Mun CW, Lee SJ, Baik SK. Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy. J Neurol 2013;260:2094-2101.
12. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679-2687.
13. Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 2006;21:847-852.
14. Seppi K, Schocke MF, Mair KJ, et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage 2006;31:240-245.
15. Paviour DC, Thornton JS, Lees AJ, Jäger HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007;22:68-74.
16. Ito M, Watanabe H, Kawai Y, et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007;78:722-728.
17. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
18. Pellecchia MT, Barone P, Mollica C, et al. Diffusion weighted imaging in multiple system atrophy: a comparison between clinical subtypes. Mov Disord 2009;24:689-696.
19. Nicoletti G, Rizzo G, Barbagallo G, et al. Diffusivity of cerebellar hemispheres enables discrimination of cerebellar or parkinsonian multiple system atrophy from progressive supranuclear palsy-Richardson syndrome and Parkinson disease. Radiology 2013;267:843-850.
20. Ordidge RJ, Gorell JM, Deniau JC, et al. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994;32:335-341.
21. Péran P, Hagberg G, Luccichenti G, et al. Voxel-based analysis of R2* maps in the healthy human brain. J Magn Reson Imaging 2007;26:1413-1420.
22. Péran P, Cherubini A, Luccichenti G, et al. Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp 2009;30:2667-2675.
23. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other eurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
24. Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord 2006;21:1299-1310.
25. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012;46:1-18.
26. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications [Review]. AJR Am J Roentgenol 1992;159:591-599.
27. Ghaemi M, Hilker R, Rudolf J, Scobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002;73:517-523.
28. Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012;33:266-273.
29. Han YH, Lee JH, Kang BM, Mun CW, Baik SK, Shin YI, Park KH. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. J Neurol Sci 2013;325:29-35.
30. Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage. 2004;21:1443-1451.
31. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
32. Rinne JO, Burn DJ, Mathias CJ, Quinn NP, Marsden CD, Brooks DJ. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol 1995;37:568-573.
33. Lu CS, Weng YH, Chen MC, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med 2004;45:49-55.
34. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
35. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
37. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
38. Fahn S, Elton R, Members of the UPDRS Development Committee. Recent Developments in Parkinson's Disease. Vol 2. Florham Park. NJ: Macmillan Health Care Information; 1987.
39. Wenning GK, Tison F, Seppi K, et al. Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 2004;19:1392-1402.
40. Cherubini A, Péran P, Caltagirone C, Sabatini U, Spalletta G. Aging of subcortical nuclei: microstructural. mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 2009;48:29-36.
41. Péran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423-3433.
42. Nemmi F, Sabatini U, Rascol O, Péran P. Parkinson's disease and local atrophy in subcortical nuclei: insight from shape analysis. Neurobiol Aging 2015;36:424-433.
43. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
44. Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 2009;24:2272-2276.
45. Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages. Acad Radiol 2014;21:64-71.
46. Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One 2013;8:e57904. doi: 10.1371/journal.pone.0057904
47. Ziegler DA, Wonderlick JS, Ashourian P, et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol 2013;70:241-247.
48. Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011;18:1093-1096.
49. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol 2002;23:1747-1756.
50. Foster ER, Black KJ, Antenor-Dorsey JA, Perlmutter JS, Hershey T. Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease. Brain Cogn 2008;67:1-10.
51. Aquino D, Contarino V, Albanese A, et al. Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 2014;35:753-758.
52. Ogisu K, Kudo K, Sasaki M, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology 2013;55:719-724.
53. Lehéricy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012;27:822-830.
54. Massey LA, Yousry TA. Anatomy of the substantia nigra and subthalamic nucleus on MR imaging. Neuroimaging Clin North Am 2010;20:7-27.
55. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [123I]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-1032.
56. 123I]β-CIT and SPECT. J Neural Transm 1997;50(Suppl):9-24.
57. Song YJ, Huang Y, Halliday GM. Clinical correlates of similar pathologies in parkinsonian syndromes. Mov Disord 2011;26:499-506.
58. Du G, Lewis MM, Sen S, et al. Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord. 2012;27:1636-1643.
59. Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, Wenning GK. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
60. Pellecchia MT, Barone P, Vicidomini C, et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov Disord 2011;26:1303-1309.
61. Poewe W, Seppi K, Fitzer-Attas C, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015;14:145-152.
62. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303-312.
63. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
64. Churchyard A, Donnan GA, Hughes A, et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 1993;34:219-226.
65. Goto S, Matsumoto S, Ushio Y, Hirano A. Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration. Neurology 1996;47:1032-1036.